Abstract
Proteus mirabilis expresses several virulence factors including MR/P fimbriae and flagella. Bacterial flagellin has frequently shown interesting adjuvant and protective properties in vaccine formulations. However, native P. mirabilis flagellin has not been analyzed so far. Native P. mirabilis flagellin was evaluated as a protective antigen and as an adjuvant in co-immunizations with MrpA (structural subunit of MR/P fimbriae) using an ascending UTI model in the mouse. Four groups of mice were intranasally treated with either MrpA, native flagellin, both proteins and PBS. Urine and blood samples were collected before and after immunization for specific antibodies determination. Cytokine production was assessed in immunized mice splenocytes cultures. Mice were challenged with P. mirabilis, and bacteria quantified in kidneys and bladders. MrpA immunization induced serum and urine specific anti-MrpA antibodies while MrpA coadministered with native flagellin did not. None of the animals developed significant anti-flagellin antibodies. Only MrpA-immunized mice showed a significant decrease of P. mirabilis in bladders and kidneys. Instead, infection levels in MrpA-flagellin or flagellin-treated mice showed no significant differences with the control group. IL-10 was significantly induced in splenocytes of mice that received native flagellin or MrpA-flagellin. Native P. mirabilis flagellin did not protect mice against an ascending UTI. Moreover, it showed an immunomodulatory effect, neutralizing the protective role of MrpA. P. mirabilis flagellin exhibits particular immunological properties compared to other bacterial flagellins.
Similar content being viewed by others
References
Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S (2013) Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31:1210–1216
Bates JT, Uematsu S, Akira S, Mizel SB (2009) Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol 182:7539–7547
Braga CJ, Rittner GM, Muñoz Henao JE, Teixeira AF, Massis LM, Sbrogio-Almeida ME, Taborda CP, Travassos LR, Ferreira LC (2009) Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infect Immun 77:1700–1707
Brunner R, Jensen-Jarolim E, Pali-Schöll I (2010) The ABC of clinical and experimental adjuvants—a brief overview. Immunol Lett 128:29–35
Chan CY, St John AL, Abraham SN (2013) Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38:349–359
Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, Mohr E, MacLenna IC (2004) Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 34:2986–2995
Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J (1992) Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 175:671–682
Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, Carlsen H, Blomhoff R, Akira S, Kraehenbuhl JP, Sirard JC (2004) Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 172:6922–6930
Dielubanza EJ, Schaeffer AJ (2011) Urinary tract infections in women. Med Clin N Am 95:27–41
Duan Q, Zhou M, Zhu L, Zhu G (2012) Flagella and bacterial pathogenicity. J Basic Microbiol 52:1–8
Duell BL, Tan CK, Carey AJ, Wu F, Cripps AW, Ulett GC (2012) Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol 64:295–313
Errea A, Moreno G, Sisti F, Fernandez J, Rumbo M, Hozbor DF (2010) Mucosal innate response stimulation induced by lipopolysaccharide protects against Bordetella pertussis colonization. Med Microbiol Immunol 199:103–108
Faezi S, Safarloo M, Behrouz B, Aminmozafari N, Nikokar I, Mahdavi M (2012) Comparison between active and passive immunization with flagellin-based subunit vaccine from Pseudomonas aeruginosa in burned-mouse model. Iran J Clin Infect Dis 7:10–16
Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103
Honko AN, Mizel SB (2004) Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun 72:676–679
Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME (2008) Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 21:26–59
Jarchum I, Liu M, Lipuma L, Pamer EG (2011) Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 79:1498–1503
Johnson JR (1996) Treatment and Prevention of urinary tract infections. In: Mobley HLT, Warren JW (eds) Urinary tract infections: molecular pathogenesis and clinical management. ASM Press, Washington, pp 95–118
Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG (2010) Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J Infect Dis 201:534–543
Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, Ahn OS, Lee JJ, Song HC, Kim JM, Choy HE, Chung SS, Kweon MN, Rhee JH (2006) A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74:694–702
Legnani-Fajardo C, Zunino P, Algorta G, Laborde HF (1991) Antigenic and immunogenic activity of flagella and fimbriae preparations from uropathogenic Proteus mirabilis. Can J Microbiol 37:325–328
Legnani-Fajardo C, Zunino P, Piccini C, Allen A, Maskell D (1996) Defined mutants of Proteus mirabilis lacking flagella cause ascending urinary tract infection in mice. Microb Pathog 21:395–405
Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, Holmes RK, Mobley HLT (2004) Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun 72:7306–7310
Mizel SB, Bates JT (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677–5682
Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein–Barr virus gene BCRFI. Science 248:1230–1234
Muñoz N, Van Maele L, Marques JM, Rial A, Sirard JC, Chabalgoity JA (2010) Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun 78:4226–4233
Nicolle LE (2005) Catheter related urinary tract infection. Drugs Aging 22:627–639
Nielubowicz GR, Mobley HLT (2010) Host-pathogen interactions in urinary tract infection. Nat Rev Urol 7:430–441
Pellegrino R, Galvalisi U, Scavone P, Sosa V, Zunino P (2003) Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol Med Microbiol 15:103–110
Rather PN (2005) Swarmer cell differentiation in Proteus mirabilis. Environ Microbiol 7:1065–1073
Salyers AA, Whitt DD (1994) Bacterial pathogenesis, a molecular approach. ASM Press, Washington
Scavone P, Sosa V, Pellegrino R, Galvalisi U, Zunino P (2004) Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins. Microbes Infect 6:853–860
Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, Zunino P (2007) Intranasal immunization with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 9:821–828
Scavone P, Rial A, Umpiérrez A, Chabalgoity A, Zunino P (2009) Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract. Microbiol Immunol 53:233–240
Scavone P, Umpiérrez A, Maskell DJ, Zunino P (2011) Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract. J Med Microbiol 60:899–904
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Frujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85
Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4:1247–1253
Stamm WE, Martin SM, Bennett JV (1977) Epidemiology of nosocomial infections due to Gram-negative bacilli: aspects relevant to development and use of vaccines. J Infect Dis 136(Suppl):S151–S160
Studier FW, Moffatt BA (1985) Use of a bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113–130
Subramanian N, Qadri A (2006) Lysophospholipid sensing triggers secretion of flagellin from pathogenic salmonella. Nat Immunol 7:583–589
Tarahomjoo S (2014) Utilizing bacterial flagellins against infectious diseases and cancers. Antonie Van Leeuwenhoek 105:275–288
Umpiérrez A, Scavone P, Romanin D, Marqués JM, Chabalgoity JA, Rumbo M, Zunino P (2013) Innate immune responses to Proteus mirabilis flagellin in the urinary tract. Microbes Infect 15:688–696
Warren JW, Tenney JH, Hoopes JM, Muncie HL, Anthony WC (1982) A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 146:719–723
Yu FS, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, Gao N, Yoon SG, Gallo RL, Standiford TJ (2010) Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 185:1142–1149
Zunino P, Geymonat L, Allen AG, Legnani-Fajardo C, Maskell DJ (2000) Virulence of a Proteus mirabilis ATF isogenic mutant is not impaired in a mouse model of ascending urinary tract infection. FEMS Immunol Med Microbiol 29:137–143
Acknowledgments
This study was funded by ANII-FCE-2007_226. P. Scavone received a doctoral fellowship from ANII-BE-POS_2009_602.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scavone, P., Umpiérrez, A., Rial, A. et al. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein. Antonie van Leeuwenhoek 105, 1139–1148 (2014). https://doi.org/10.1007/s10482-014-0175-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10482-014-0175-7